PMC:7190487 / 6331-6676 JSONTXT

{"project":"LitCovid_Glycan-Motif-Structure","denotations":[{"id":"T3","span":{"begin":84,"end":91},"obj":"https://glytoucan.org/Structures/Glycans/G15021LG"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T43","span":{"begin":84,"end":91},"obj":"Body_part"},{"id":"T44","span":{"begin":128,"end":136},"obj":"Body_part"},{"id":"T45","span":{"begin":204,"end":211},"obj":"Body_part"}],"attributes":[{"id":"A43","pred":"fma_id","subj":"T43","obj":"http://purl.org/sig/ont/fma/fma82743"},{"id":"A44","pred":"fma_id","subj":"T44","obj":"http://purl.org/sig/ont/fma/fma83350"},{"id":"A45","pred":"fma_id","subj":"T45","obj":"http://purl.org/sig/ont/fma/fma83365"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T40","span":{"begin":242,"end":250},"obj":"Disease"},{"id":"T41","span":{"begin":268,"end":276},"obj":"Disease"}],"attributes":[{"id":"A40","pred":"mondo_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A41","pred":"mondo_id","subj":"T41","obj":"http://purl.obolibrary.org/obo/MONDO_0005015"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T102","span":{"begin":142,"end":149},"obj":"http://purl.obolibrary.org/obo/PR_000018263"},{"id":"T103","span":{"begin":204,"end":211},"obj":"http://purl.obolibrary.org/obo/PR_000009054"},{"id":"T104","span":{"begin":284,"end":286},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T80","span":{"begin":84,"end":91},"obj":"Chemical"},{"id":"T83","span":{"begin":106,"end":116},"obj":"Chemical"},{"id":"T84","span":{"begin":128,"end":136},"obj":"Chemical"},{"id":"T85","span":{"begin":142,"end":149},"obj":"Chemical"},{"id":"T86","span":{"begin":182,"end":194},"obj":"Chemical"},{"id":"T87","span":{"begin":204,"end":211},"obj":"Chemical"},{"id":"T88","span":{"begin":322,"end":331},"obj":"Chemical"}],"attributes":[{"id":"A80","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_17234"},{"id":"A81","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_4167"},{"id":"A82","pred":"chebi_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/CHEBI_42758"},{"id":"A83","pred":"chebi_id","subj":"T83","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A84","pred":"chebi_id","subj":"T84","obj":"http://purl.obolibrary.org/obo/CHEBI_5391"},{"id":"A85","pred":"chebi_id","subj":"T85","obj":"http://purl.obolibrary.org/obo/CHEBI_16670"},{"id":"A86","pred":"chebi_id","subj":"T86","obj":"http://purl.obolibrary.org/obo/CHEBI_8228"},{"id":"A87","pred":"chebi_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/CHEBI_5931"},{"id":"A88","pred":"chebi_id","subj":"T88","obj":"http://purl.obolibrary.org/obo/CHEBI_6801"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T58","span":{"begin":84,"end":103},"obj":"http://purl.obolibrary.org/obo/GO_1904659"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-sentences","denotations":[{"id":"T53","span":{"begin":0,"end":345},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}

{"project":"LitCovid-PubTator","denotations":[{"id":"267","span":{"begin":204,"end":211},"obj":"Gene"},{"id":"276","span":{"begin":84,"end":91},"obj":"Chemical"},{"id":"277","span":{"begin":182,"end":194},"obj":"Chemical"},{"id":"278","span":{"begin":322,"end":331},"obj":"Chemical"},{"id":"285","span":{"begin":242,"end":250},"obj":"Disease"},{"id":"286","span":{"begin":268,"end":276},"obj":"Disease"}],"attributes":[{"id":"A267","pred":"tao:has_database_id","subj":"267","obj":"Gene:3630"},{"id":"A276","pred":"tao:has_database_id","subj":"276","obj":"MESH:D005947"},{"id":"A277","pred":"tao:has_database_id","subj":"277","obj":"MESH:D000077205"},{"id":"A278","pred":"tao:has_database_id","subj":"278","obj":"MESH:D008687"},{"id":"A285","pred":"tao:has_database_id","subj":"285","obj":"MESH:C000657245"},{"id":"A286","pred":"tao:has_database_id","subj":"286","obj":"MESH:D003920"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Although recent discussions point out that oral hypoglycaemic agents such as Sodium-Glucose-Transporter-2 inhibitors (SGLT-2i), Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1RAs), Pioglitazone and even Insulin might actually be harmful for COVID-19 individuals with diabetes [21], [22], limited evidence is available on metformin for the same."}